VANCOUVER, Wash., Jan. 9, 2019 /PRNewswire/ -- AbSci, a global leader in biotherapeutic discovery and manufacturing technologies,
"It is exciting to partner with a renowned company like Sanofi," said Sean McClain, CEO of AbSci. "This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We've shown SoluProTM can uniquely deliver on this industry need."
AbSci is a global leader in biomanufacturing technologies. Its patented SoluPro expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides to the most novel classes of biotherapeutics, at high-titers and high-quality. AbSci's unique approach increases discovery throughput, accelerates development, reduces manufacturing costs, and increase plant capacity for the biopharmaceutical industry. For more information, please visit www.absci.com.
View original content:http://www.prnewswire.com/news-releases/absci-establishes-new-collaboration-with-sanofi-300775436.html
Subscribe to our Free Newsletters!